Literature DB >> 7824134

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

J B Rich1, D X Rasmusson, M F Folstein, K A Carson, C Kawas, J Brandt.   

Abstract

We reviewed the records of 210 patients in the Johns Hopkins Alzheimer's Disease Research Center to evaluate the role of nonsteroidal anti-inflammatory drugs (NSAIDs) on clinical features and progression of the disease. We compared patients taking NSAIDs or aspirin on a daily basis (N = 32) to non-NSAID patients (N = 177) on clinical, cognitive, and psychiatric measures. The NSAID group had a significantly shorter duration of illness at study entry. Even after controlling for this difference, the NSAID group performed better on the Mini-Mental State Examination, Boston Naming Test, and the delayed condition of the Benton Visual Retention Test. Furthermore, analysis of longitudinal changes over 1 year revealed less decline among NSAID patients than among non-NSAID patients on measures of verbal fluency, spatial recognition, and orientation. These findings support other recent studies suggesting that NSAIDs may serve a protective role in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7824134     DOI: 10.1212/wnl.45.1.51

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  77 in total

1.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation.

Authors:  Saba Aid; Nishant Parikh; Sara Palumbo; Francesca Bosetti
Journal:  Neurosci Lett       Date:  2010-05-06       Impact factor: 3.046

Review 3.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

4.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 5.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 6.  Prevention of Alzheimer's disease: where we stand.

Authors:  Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 7.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

8.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 9.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

10.  Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview.

Authors:  D Metodiewa; C Kośka
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.